Latent Tuberculosis Infection Detection Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The Latent Tuberculosis Infection Detection Market focuses on identifying individuals carrying M. tuberculosis bacteria without showing active symptoms, a critical step in preventing disease progression and transmission. Current market valuation at $2.0 billion reflects robust demand from healthcare systems implementing proactive screening protocols and the transition from older diagnostic methods to more accurate blood-based assays.

• •Market size approximately $2.0 billion USD in 2025
• •Annual growth rate of 5.9% CAGR projected through the forecast period
• •Primary test categories include tuberculin skin tests, interferon-gamma release assays, and molecular diagnostics

Expanding tuberculosis elimination programs and rising awareness among healthcare providers fuel demand for reliable LTBI diagnostics. Government-mandated screening for immigrants, healthcare workers, and high-risk populations creates steady institutional demand for these testing solutions across both developed and developing regions.

• •WHO End TB Strategy and national health agencies prioritize active case finding and preventive therapy
• •Immigration and occupational screening mandates drive consistent testing volumes
• •Superior accuracy, convenience, and lower false-positive rates of newer assays accelerate adoption rates

The market spans test types including IGRA blood tests, tuberculin skin tests, and emerging molecular diagnostics, each serving different clinical settings and patient populations. Geographic distribution reflects regional TB burden, healthcare infrastructure development, and screening program implementation levels.

• •North America leads with high screening rates for high-risk populations and advanced healthcare infrastructure
• •Asia-Pacific represents the fastest-growing region driven by high disease burden, large populations, and expanding diagnostic access
• •Europe maintains significant market share through systematic screening programs for immigrants and healthcare workers

What are the recent trends and outlook?

The market is shifting toward blood-based IGRAs that eliminate variability associated with skin test administration and reading, while point-of-care testing capabilities simplify workflows in resource-limited settings. Emerging technologies combining LTBI detection with active TB diagnosis and digital health integration are expected to reshape the competitive landscape through 2030.

• •IGRA adoption continues replacing traditional tuberculin skin tests in high-income countries
• •Point-of-care and cartridge-based molecular platforms expand testing access in low-resource settings
• •Combination assays and AI-assisted interpretation tools represent emerging innovation frontiers